• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BetterInvesting™ Magazine Update on Amphastar Pharmaceuticals Inc. and Medtronic PLC

    6/14/24 4:30:00 PM ET
    $AMPH
    $MDT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $AMPH alert in real time by email

    TROY, Mich., June 14, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) as its "Stock to Study" and Medtronic PLC (NYSE:MDT) as its "Undervalued Stock" in the September 2024 issue for investors' informational and educational use.

    "With GameStop back in the headlines, the siren song of easy money has returned, luring the unschooled down treacherous paths. The National Association of Investors counsels everyday Americans seeking long term wealth to focus on fundamentals and learn to earn," said Ken Zendel, CEO of National Association of Investors Corp. (NAIC), the parent organization of BetterInvesting.

    For a refresher on GameStop vs. the fundamentals, read:

    https://www.betterinvesting.org/learn-about-investing/investor-education/investing/market-madness-short-selling-short-squeeze

    Check the September 2024 issue of BetterInvesting Magazine for more details about the latest stocks. Non-members can utilize the limited, trial version of the BetterInvesting online stock selection and analysis tools to study the investment potential of Amphastar Pharmaceuticals and Medtronic by viewing their fundamental data and applying judgments.

    Committee members are Dan Rutter, CFA; Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; and Anne Nichols, CFA; Lauren Adams, CFA.

    As stated, the BetterInvesting committee's Stock to Study and Undervalued Stock choices are for the informational and educational uses of investors. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. BetterInvesting urges investors to educate themselves about the stock market so they can make informed decisions about stock purchases. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

    About BetterInvesting:

    BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

    Follow us on LinkedIn and Facebook.

    Contact: 877-275-6242

    Cision View original content:https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-amphastar-pharmaceuticals-inc-and-medtronic-plc-302173374.html

    SOURCE NAIC-BetterInvesting

    Get the next $AMPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMPH
    $MDT

    CompanyDatePrice TargetRatingAnalyst
    Medtronic plc.
    $MDT
    2/13/2026$116.00Overweight
    Barclays
    Medtronic plc.
    $MDT
    2/9/2026$121.00Hold → Buy
    Needham
    Medtronic plc.
    $MDT
    2/3/2026$117.00Buy
    Citigroup
    Medtronic plc.
    $MDT
    1/30/2026$114.00Overweight
    Wells Fargo
    Medtronic plc.
    $MDT
    1/6/2026Mkt Perform → Outperform
    William Blair
    Amphastar Pharmaceuticals Inc.
    $AMPH
    12/9/2025$30.00Equal Weight
    Barclays
    Medtronic plc.
    $MDT
    11/19/2025$111.00Sell → Neutral
    Goldman
    Amphastar Pharmaceuticals Inc.
    $AMPH
    8/12/2025$36.00Hold → Buy
    Needham
    More analyst ratings

    $AMPH
    $MDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medtronic to acquire Scientia Vascular, marrying access and therapeutic portfolios for neurovascular care

    Deal complements Medtronic's Neurovascular portfolio, delivering simplicity and access when 'time is brain'GALWAY, Ireland, March 10, 2026 /PRNewswire/ -- Medtronic today announced its entry into a definitive agreement to acquire Scientia Vascular, a company with critical, innovative technology across the neurovascular portfolio. The acquisition is valued at $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments post-acquisition.Scientia is a private company operating in Salt Lake City, Utah, with approximately 310 employees. Under founder and current chief technology officer John Lippert, the company has developed best-in-class access prod

    3/10/26 6:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    MiniMed to begin trading on Nasdaq Global Select Market

    GALWAY, Ireland, March 6, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, announced that MiniMed Group, Inc. (NASDAQ:MMED) will begin trading today on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol "MMED" in connection with its initial public offering ("IPO")."Today marks an exciting milestone for both MiniMed and Medtronic. Despite a challenging market backdrop shaped by geopolitical uncertainty, the teams successfully executed an oversubscribed offering and the second largest IPO in Medtech history," said Geoff Martha, Medtronic chairman and chief executive officer. "Establishing MiniMed as a standalone entity positions the company

    3/6/26 9:00:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    MiniMed announces pricing of initial public offering

    GALWAY, Ireland and NORTHRIDGE, Calif., March 5, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed), a subsidiary of Medtronic plc (Medtronic) (NYSE:MDT), today announced the pricing of its initial public offering (IPO) of 28,000,000 shares of its common stock at a price to the public of $20.00 per share. The shares are expected to begin trading on the Nasdaq Global Select Market (Nasdaq) on March 6, 2026, under the symbol "MMED." The offering is expected to close on March 9, 2026, subject to customary closing conditions. MiniMed has granted the underwriters a 30-day option to p

    3/5/26 7:33:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AMPH
    $MDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Amphastar Pharmaceuticals Inc.

    4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

    3/10/26 9:03:09 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Amphastar Pharmaceuticals Inc.

    4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

    3/10/26 5:44:10 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Amphastar Pharmaceuticals Inc.

    4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

    3/10/26 5:41:43 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    $MDT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for MEDROXYPROGESTERONE ACETATE issued to AMPHASTAR PHARMS INC

    Submission status for AMPHASTAR PHARMS INC's drug MEDROXYPROGESTERONE ACETATE (SUPPL-5) with active ingredient MEDROXYPROGESTERONE ACETATE has changed to 'Approval' on 01/25/2024. Application Category: ANDA, Application Number: 077334, Application Classification: Labeling

    1/26/24 4:40:02 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for CORTROSYN issued to AMPHASTAR PHARMS INC

    Submission status for AMPHASTAR PHARMS INC's drug CORTROSYN (SUPPL-33) with active ingredient COSYNTROPIN has changed to 'Approval' on 12/22/2023. Application Category: NDA, Application Number: 016750, Application Classification: Labeling

    12/27/23 4:38:39 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NALOXONE HYDROCHLORIDE issued to AMPHASTAR PHARMS INC

    Submission status for AMPHASTAR PHARMS INC's drug NALOXONE HYDROCHLORIDE (SUPPL-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 06/29/2023. Application Category: NDA, Application Number: 208969, Application Classification: Labeling

    6/30/23 9:33:25 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    $MDT
    SEC Filings

    View All

    Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

    3/6/26 4:17:52 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

    3/6/26 4:12:50 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Amphastar Pharmaceuticals Inc.

    10-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

    2/26/26 4:41:58 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    $MDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Medtronic with a new price target

    Barclays resumed coverage of Medtronic with a rating of Overweight and set a new price target of $116.00

    2/13/26 8:31:53 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic upgraded by Needham with a new price target

    Needham upgraded Medtronic from Hold to Buy and set a new price target of $121.00

    2/9/26 6:45:10 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Citigroup resumed coverage on Medtronic with a new price target

    Citigroup resumed coverage of Medtronic with a rating of Buy and set a new price target of $117.00

    2/3/26 6:56:06 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AMPH
    $MDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jellison William R bought $462,750 worth of Ordinary Shares (5,000 units at $92.55) (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/25/25 5:18:06 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AMPH
    $MDT
    Financials

    Live finance-specific insights

    View All

    Medtronic announces cash dividend for fourth quarter of fiscal year 2026

    GALWAY, Ireland, March 5, 2026 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 5, 2026, approved the company's cash dividend for the fourth quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on April 17, 2026, to shareholders of record at the close of business on March 27, 2026.About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquarte

    3/5/26 4:53:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters

    Cardiovascular portfolio up 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolioGALWAY, Ireland, Feb. 17, 2026 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its third quarter (Q3) of fiscal year 2026 (FY26), which ended January 23, 2026.Q3 Key HighlightsRevenue of $9.0 billion, increased 8.7% as reported and 6.0% organic, 50 basis points ahead of Q3 guidanceGAAP diluted EPS of $0.89; non-GAAP diluted EPS of $1.36, three cents ahead of Q3 guidance mid-pointCompany reiterates FY26 organic revenue growth and EPS guidanceCardiac Ablation Solutions revenue increased 80%, includin

    2/17/26 6:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic announces cash dividend for third quarter of fiscal year 2026

    GALWAY, Ireland, Dec. 4, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 4, 2025, approved the company's cash dividend for the third quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on January 16, 2026, to shareholders of record at the close of business on December 26, 2025. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, hea

    12/4/25 4:32:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AMPH
    $MDT
    Leadership Updates

    Live Leadership Updates

    View All

    Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

    GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent.  Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu

    7/8/25 8:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic Board appoints Dr. Joon Lee as a new director

    GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec

    6/23/25 4:15:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

    NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

    3/31/25 4:21:30 PM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    $AMPH
    $MDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

    3/6/24 10:23:26 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/13/24 5:09:43 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

    2/13/24 4:58:53 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care